Literature DB >> 20339989

Inhibition of osteopontin reduces liver metastasis of human pancreatic cancer xenografts injected into the spleen in a mouse model.

Keisuke Ohno1, Hidefumi Nishimori, Takahiro Yasoshima, Kenjiro Kamiguchi, Fumitake Hata, Rika Fukui, Koichi Okuya, Yasutoshi Kimura, Ryuichi Denno, Shigeyuki Kon, Toshimitsu Uede, Noriyuki Sato, Koichi Hirata.   

Abstract

PURPOSE: Pancreatic cancer is associated with the poorest prognosis of any digestive cancer due to the high incidence of liver metastasis. This study evaluated the possibility that osteopontin (OPN) RNA interference (RNAi) and anti-OPN antibody (Ab) could have antimetastatic effects.
METHODS: The differential gene expression was measured in a parental cell line, HPC-3, and an established highly liver metastatic cell line, HPC-3H4. This study investigated the effect of OPN RNAi and anti-OPN Ab on the metastatic ability of HPC-3H4 to the liver. An OPN RNAi-expressing vector was introduced into HPC-3H4 cells (HPC-3H4/miOPN), in which OPN production was reduced to the level of the parental HPC-3 cells. Finally, the ability of anti-OPN Ab to suppress liver metastasis was investigated.
RESULTS: Osteopontin was upregulated 11.1-fold in HPC-3H4 in comparison to HPC-3. The metastatic rate of HPC-3H4/miOPN was significantly reduced to 25% in comparison to the 100% metastatic rate of HPC-3H4 and control HPC-3H4/miNeg cells (P < 0.01). The metastatic rate of the group given anti-OPN Ab was 50%.
CONCLUSION: OPN RNAi and anti-OPN Ab had remarkable inhibitory effects against liver metastasis by the pancreatic cancer cell line.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20339989     DOI: 10.1007/s00595-009-4082-x

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  33 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts.

Authors:  A Miyauchi; J Alvarez; E M Greenfield; A Teti; M Grano; S Colucci; A Zambonin-Zallone; F P Ross; S L Teitelbaum; D Cheresh
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

3.  Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.

Authors:  N Shijubo; T Uede; S Kon; M Maeda; T Segawa; A Imada; M Hirasawa; S Abe
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

4.  Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.

Authors:  A Kolb; J Kleeff; A Guweidhi; I Esposito; N A Giese; H Adwan; T Giese; M W Büchler; M R Berger; H Friess
Journal:  Cancer Biol Ther       Date:  2005-07-05       Impact factor: 4.742

5.  The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

6.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

7.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

8.  Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis.

Authors:  Nobuchika Yamamoto; Fumihiko Sakai; Shigeyuki Kon; Junko Morimoto; Chiemi Kimura; Harumi Yamazaki; Ikuko Okazaki; Nobuo Seki; Takashi Fujii; Toshimitsu Uede
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

9.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

10.  Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis.

Authors:  Jian Zhao; Li Dong; Bin Lu; Guobin Wu; Dongmei Xu; Jingjing Chen; Kai Li; Xin Tong; Jianxin Dai; Side Yao; Mengchao Wu; Yajun Guo
Journal:  Gastroenterology       Date:  2008-05-07       Impact factor: 22.682

View more
  4 in total

Review 1.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

2.  Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice.

Authors:  Kyeong-Nam Yu; Arash Minai-Tehrani; Seung-Hee Chang; Soon-Kyung Hwang; Seong-Ho Hong; Ji-Eun Kim; Ji-Young Shin; Sung-Jin Park; Ji-Hye Kim; Jung-Taek Kwon; Hu-Lin Jiang; Bitna Kang; Duyeol Kim; Chan-Hee Chae; Kee-Ho Lee; Tae-Jong Yoon; George R Beck; Myung-Haing Cho
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

Review 3.  The role of osteopontin in the progression of solid organ tumour.

Authors:  Hailin Zhao; Qian Chen; Azeem Alam; Jiang Cui; Ka Chun Suen; Aurelie Pac Soo; Shiori Eguchi; Jianteng Gu; Daqing Ma
Journal:  Cell Death Dis       Date:  2018-03-02       Impact factor: 8.469

Review 4.  The Role of Adipokines in Pancreatic Cancer.

Authors:  Qi Wang; Huizhi Wang; Yuntao Ding; Mengtian Wan; Min Xu
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.